Last reviewed · How we verify
Iodophor (10% povidone-iodine)
Povidone-iodine releases iodine that oxidizes and denatures microbial proteins and nucleic acids, providing broad-spectrum antimicrobial activity.
Povidone-iodine releases iodine that oxidizes and denatures microbial proteins and nucleic acids, providing broad-spectrum antimicrobial activity. Used for Skin antisepsis and wound disinfection, Surgical site preparation, Minor cuts, scrapes, and burns.
At a glance
| Generic name | Iodophor (10% povidone-iodine) |
|---|---|
| Sponsor | University of California, Irvine |
| Drug class | Topical antiseptic/disinfectant |
| Modality | Small molecule |
| Therapeutic area | Infection prevention and control |
| Phase | FDA-approved |
Mechanism of action
The iodine component penetrates microbial cell membranes and oxidizes essential proteins, enzymes, and DNA/RNA, leading to rapid cell death. This mechanism is effective against bacteria, viruses, fungi, and some protozoa. The povidone carrier enhances stability and sustained release of iodine at the site of application.
Approved indications
- Skin antisepsis and wound disinfection
- Surgical site preparation
- Minor cuts, scrapes, and burns
- Oral and throat antisepsis
Common side effects
- Local irritation or burning
- Allergic contact dermatitis
- Iodine sensitivity reactions
- Staining of skin and clothing
Key clinical trials
- Surgical Site Preparation in Subjects Undergoing Medical Thoracoscopy (NA)
- Povidone Iodine Efficacy Study (PHASE2)
- Vancomycin Powder and Dilute Povidone Iodine Lavage for Infection Prophylaxis in High Risk Total Joint Arthroplasty (PHASE1)
- Nasal Antisepsis for C. Auris Prevention (PHASE4)
- Combined Use of Povidone-Iodine and Rifampicin in Hair Transplantation (NA)
- Povidone-Iodine Versus Chlorhexidine in Surgical Wound Care (NA)
- Mupirocin-Iodophor ICU Decolonization Swap Out Trial (PHASE4)
- Betadine Versus Saline in Swapping of Subcutaneous Tissue (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |